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(χ2  =  5.227, P = 0.022), and 4/15 primary tumors and 
12/15 s regrowth tumors (χ2 = 8.571, P = 0.003). There was 
no statistically significant difference in  Ki-67 expression 
between primary and second recurrent/regrowth tumors 
although theKi67 labeling index was higher in the lat-
ter groups. RB was highly expressed in all groups with no 
significant difference between them. HMGA1 and MDM2 
were more highly expressed in recurrence/regrowth cases 
of NFPA than in primary NFPA. HMGA1 and MDM2 are 
biomarkers and potential drug targets for NFPA treatment.
Keywords Nonfunctioning pituitary adenoma · Tissue 
microarray · Recurrence · Regrowth · HMGA1 · MDM2
Background
Nonfunctioning pituitary adenomas (NFPAs) are the most 
prevalent type of pituitary macroadenoma, accounting 
for 25–35% of all cases [1]. Although they are generally 
benign, many invade the sphenoid, cavernous sinus, or 
dura mater and may be incompletely removed by surgical 
resection. The remnant tumor can potentially regrow since 
residual cells retain their ability to proliferate, necessitat-
ing a second therapeutic intervention [2]. Most cases of 
recurrence occur within 5 years after surgery [3]. Owing to 
the high rate of long-term recurrence, patient prognosis is 
not always favorable [4]. The main therapeutic option for 
NFPA is surgical and there are currently no pharmacologic 
treatments available. A variety of histological biomark-
ers for NFPA have been investigated for their relationship 
to invasiveness and tumor recurrence, including the pro-
liferation marker Ki-67, cellcycle-related factors such as 
p27 and galectin-3, and other molecules such as p53,O-
6-methylguanine-DNA methyltransferase, and matrix 
Abstract Nonfunctioning pituitary adenomas (NFPAs) 
are the most prevalent type of pituitary macro-adenoma. 
Clarifying the relationship between NFPA markers and 
disease progression or recurrence could provide a basis 
for administration of adjuvant treatments. The present 
study examined the expression levels of high-mobility 
group (HMG)A1, Ki-67, mouse double minute 2 homolog 
(MDM2), and retinoblastoma (RB)with respect to NFPA 
recurrence. Immunohistochemistry was carried out using 
antibodies to Ki-67, MDM2, HMGA-1, and RB on tissue 
microarray slides of a cohort of 35 paired NFPA samples 
of primary and recurrence/regrowth tumors. Based on 
postoperative magnetic resonance imaging data, tumors 
were classified as recurrence (n = 20) included primary and 
recurrent tumors or regrowth (n = 15) included primary 
and regrowth tumors, which are paired. Protein expres-
sion was classified as negative or positive according to the 
H-score method and was analyzed with respect to clinical 
and pathological findings. MDM2-positive cases accounted 
for11/20 primary and 19/20 s recurrent tumors (χ2 = 8.533, 
P = 0.003), and 9/15 primary tumors and 15/15 s regrowth 
tumors (χ2 = 7.5, P = 0.006). MGA1-positive cases repre-
sented 9/20 primary tumors and 16/20  s recurrent tumors 
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metalloproteinase 9 [5–7]. However, given the absence of 
reliable serum markers for detecting residual tumor cells, 
the decision on whether to recommend additional interven-
tion is typically made based on postoperative imaging.
The high-mobility group (HMG)A family of proteins 
has four members; one of these, HMGA1, plays a criti-
cal role in cancer progression, development, and metabo-
lism, among others [8]. HMGA proteins are expressed at 
low levels in normal adult tissues and cells, but is upregu-
lated in many tumors, neoplastically transformed cells, and 
embryonic stem cells [9]. HMGA overexpression is associ-
ated with poor prognosis due to metastasis [10]. HMGA1 
has been linked to pituitary tumor progression, consistent 
with its critical role in cell cycle regulation [11]. HMGA2 
is associated with the retinoblastoma (RB)-E2F pathway in 
pituitary cell proliferation [12]; RB protein is also involved 
in cell cycle control. Unlike HMGA2, the role of HMGA1 
in pituitary tumorigenesis remains poorly understood. The 
expression of HMGA1 suggests a link to a secondary event 
in pituitary gland tumorigenesis [11].
Mouse double minute 2 homolog (MDM2) plays a criti-
cal role in the regulation of the tumor suppressor protein 
p53 [13]; MDM2 overexpression inhibits p53 activation, 
leading to evasion of the cell cycle checkpoint and carcino-
genesis [14, 15]; it is also overexpressed in many human 
malignancies [16]. Ki-67 is a reliable cell proliferation 
marker in immunohistochemistry (IHC) used to assess 
tumor progression in routine histological analyses [17]. 
Although it is routinely applied to pituitary adenomas, its 
prognostic significance remains controversial [18, 19].
Tissue microarrays (TMAs) are assembled from many 
tissue samples in a single paraffin block to increase the 
throughput and performance of molecular profiling studies 
in tumors, and can reduce experimental variables and con-
serve tissue samples. In this study we used TMAs to evalu-
ate the expression of HMGA1, Ki-67, MDM2, and RB in 
35 paired NFPA cases of primary and recurrent/regrowth 
tumors to identify a suitable marker for NFPA progression.
Materials and methods
Patients
This retrospective study included 35 patients at the Beijing 
Tiantan Hospital, Captital Medical University, who under-
went transphenoidal or transcranial operation from January 
2008 to December 2013.Tumors were all NFPAs accord-
ing to the 2007 WHO histologic classification. According 
to Knosp classification and records of operation, NFPAs 
included non-invasive and invasive tumors (Table1). There 
were classified into recurrence group included primary 
and recurrenttumors which are paired and regrowth group 
included primary and regrowth tumors which are paired. 
Recurrence was diagnosed in 20 patients when a new 
tumor was histologically confirmed, Regrowth in 15 
patients was diagnosed by the growth of a residual tumor, 
which was evaluated by a neurosurgeon and two neurora-
diologists who were blinded to the patient’s characteristics 
(see in Sheme 1). The study was carried out according to 
an institutional review board-approved protocol, and writ-
ten; informed consent was obtained from all patients prior 
to surgery.
TMA construction
Formalin-fixed, paraffin-embedded tissue blocks were 
stained with hematoxylin and eosin (H&E). Three core 
biopsies with a diameter of 2.0  mm were transferred to 
TMAs using the Leica BOND-III fully automated arrayer 
(Leica Biosystems, Wetzlar, Germany). The core samples 
were randomly ordered and the pathologist was blinded 
with respect to their location on the TMA slides. TMAs 
were cut into 4-µm sections using a serial microtome and 
placed in a water bath at 50 °C; the sections were trans-
ferred to positively-charged glass slides, deparaffinized, and 
rehydrated through a graded series of alcohol with water as 
the final solution. Slides were dried at room temperature for 
24–48 h and stored in a freezer at −80 °C until use. To min-
imize loss of antigenicity, sections were processed within 
1 week of cutting [20].
IHC
Tumor content and quality were evaluated in TMA slides 
by H&E staining. Antibodies against the following pro-
teins were used under the indicated conditions: Ki67 
(Abcam, Cambridge, UK), protocol F, with 20  min of 
epitope retrieval (ER) and 15 min of heat-induced epitope 
retrieval (HIRE); MDM2 (Abcam), with 3 min of ER and 
30 min of HIRE; HMGA1 (1:3000; Abcam),with 20 min 
of ER and 15 min of HIRE; and RB (1:500; Abcam) with 
30 min of ER and 30 min of HIRE. Bond Polymer Refine 
Detection (DS9800; Leica Biosystems) was used to detect 
the primary antibodies. The slides were scanned as digital 
images using Aperio AT2 (Leica Biosystems). The inten-
sity of staining was calculated by two neuropathologists 
who were blinded to the patient’s clinical and radiologic 
information.
TMA scanning and image analysis
Antigen labeling index (LI) was determined by count-
ing the number of positive cells in a total of 1000 tumor 
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cells in the maximally stained region at high magni-
fication (400×). The staining intensity was stratified 
on a scale of 0–3 (0 = no staining, 1 = weak, 2 = mod-
erate, and 3 = strong). An H-score was obtained 
by multiplying the staining intensity with a con-
stant to adjust the mean to the strongest staining 
[score = 1.0(%weak) + 2.0(%moderate) + 3.0(%strong)].
Statistical analysis
The χ2 test was used to assess the significance of asso-
ciations among HMGA1, Ki67, MDM2, and RB expres-
sion and clinical parameters. Differences were considered 
statistically significant at P < 0.05. Analyses were car-




We selected 35 consecutive patients diagnosed with 
NFPA for whom primary and recurrent; primary and 
regrowth tumor specimens were available, which are 
paired. Visual disturbance (23/35, 65.7%) was the most 
common clinic symptom, followed by headache (22/35, 
62.8%) and visual field deficits (13/35, 37.1%). Tumor 
recurrence was detected in 9 male and 11 female patients, 
with a mean recurrence time of 35.8  months (range: 
10–68  months). Most patients (18/20, 90%) experi-
enced recurrence within 5  years, with a mean time of 
32.4 months (range: 10–55 months). Tumor regrowth was 
observed in 4 male and 11 female patients, with a mean 
regrowth time of 25.4  months (range: 6–58  months). 
Patient characteristics are summarized in Table  1; there 




Primary Recurrence Primary Regrowth
Number 20 20 15 15
Age (year)
 Range 20–57 21–63 21–59 22–62
 Median 37 41 38 41
 Mean 37.55 41.45 39.4 41.7
Sex
 Male 9 9 4 4
 Female 11 11 11 11
Head ache 14 10 8 8
Diminution of vision 12 8 11 7
Visual field defect 7 4 6 7
Incidental/reexamine 2 3 2 3
Knosp grading
 Grade1 5 4 0 0
 Grade2 7 9 5 3
 Grade3a 4 3 1 1
 Grade3b 4 1 2 3
 Grade4 0 3 7 8
Invasive
 Yes 7 5 10 11
 No 13 15 5 4
Volume  (cm3)
 Range 1.144–19.06 2.700–21.00 1.092–51.28 1.825–36.52
 Median 7.182 6.000 14.18 10.50
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was no difference found with respect to gender, age, 
tumor size, or invasion among groups.
HMGA1, Ki67, MDM2, and RB expression in recurrent 
NFPA
Samples were scored for nuclear expression of HMGA1, 
Ki67, MDM2 and RB. Of the 20 samples, nine were 
HMGA1-positive, with Hscores of 43.75 and 100 for pri-
mary and recurrent tumors, respectively (χ2  =  5.227, 
P = 0.022; Fig.  1a, b). There were 11/20 MDM2-positive 
cases, with H-scores of 65.45 and 170 for primary and 
recurrent tumors, respectively (χ2  =  8.533, P = 0.003; 
Fig.  2a, b). There were no statistically significant differ-
ences in rates of RB positivity between the primary and 
recurrent tumor groups, although the H-score was higher 
in the latter (Table  2).Ki-67 is a marker for proliferating 
cells in neoplastic lesions; the Ki-67 LI was found to be in 
the range of 0–12.4% for moderate immunoreactivity (2+), 
with mean values of 2.76 and 4.09% for primary and recur-
rent groups, respectively.
HMGA1, Ki67, MDM2, and RB expression in regrowth 
NFPA
Among the 15 cases of regrowth NFPA, four were 
HMGA1-positive with H-scores of 16.84 and 76.67 for 
residual and regrowth tumors, respectively (χ2 = 8.571, 
P = 0.003; Fig.  1c, d). There were nine MDM2-positive 
cases, with H-scores of 71.58 and 146 for residual and 
regrowth tumors, respectively (χ2 = 7.5, P = 0.006; Fig. 2c, 
d). There was no statistically significant difference in the 
rates of RB positivity between the primary and regrowth 
tumor groups, although the H-score was slightly higher in 
the latter (Table 3). The mean Ki-67 LI was 2.52 and 3.43 
in the residual and regrowth groups, respectively. To assess 
the significance of HMGA1 and MDM2 over expression in 
NFPA, we examined the relationship between HMGA1 and 
MDM2 immunoreactivity and clinicopathologic features. 
There were no significant differences in terms of gender, 
age, tumor size, and invasion between primary tumor and 
recurrence/regrowth groups.
Discussion
Surgery is still the first and only treatment option for treat-
ing NFPA, and can rapidly improve clinical symptoms, 
including the headache, visual disturbance, and visual field 
deficits observed in this study. Visual disturbances due to 
compression of the optic apparatus are common, occurring 
in 30.8–67.8% of cases [21, 22], whereas visual field defi-
cits related to compression of the optic chiasm are observed 
in 60.8% of patients [23]. The frequency of headaches 
Scheme  1  a First postoperative MR image demonstrating com-
plete tumor removal in a 30-year-old women. b MRI scan obtained 
24  months after surgery shows a distinct tumor recurrence in the 
sellar. c First postoperative MR image demonstrating incomplete 
tumor removal in a 41-year-old men. d MRI scan obtained 58 months 
after surgery shows a distinct tumor regrowth in the sella
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Fig. 1  The expression level 
of HMGA1. a In the primary 
tumor specimens. b In the 
recurrence tumor specimens. c 
In the residual tumor speci-
mens. d In the regrowth tumor 
specimens. ×200
Fig. 2  The expression level of 
MDM2. a In the primary tumor 
specimens. b In the recurrence 
tumor specimens. c In the 
residual tumor specimens. d In 
the regrowth tumor specimens. 
×200
Table 2  The HMGA1, MDM2, 
Ki67 and RB level in recurrence 
group
Gene HMGA1 MDM2 Ki67 RB
Classification (−) (+) H-Score (−) (+) H-Score (−) (+) H-Score (−) (+) H-Score
Primary 11 9 43.75 9 11 65.45 19 1 2.76 3 17 80.43
Recurrence 4 16 100 1 19 170 17 3 4.09 0 20 138
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varies between 9.7 and 60.8% [21–23]. In our study, 90% of 
patients showed recurrence within 5 years, consistent with 
a previous report that the majority of cases show recur-
rence between 1 and 5 years after surgery [24].
This is the first study to compare the expression of 
Ki-67, MDM2, HMGA1, and RB in paired primary and 
recurrent/regrowth NFPA specimens. HMGA, MDM2, and 
RB regulate different points of the cell cycle and therefore 
play critical roles in pituitary cell proliferation and pituitary 
adenoma development. We found no difference in the lev-
els of these proteins between the recurrence and regrowth 
groups, suggesting a higher risk associated with non-radi-
cal excision of recurrent adenoma. A microsurgical transs-
phenoidal approach was used in most patients in this study, 
which often does not include the whole medial cavernous 
sinus wall; therefore, patients should be closely monitored 
for tumor recurrence [25], although post-operative residual 
adenoma is not an independent predictor of recurrence [26].
Modern molecular genetic techniques have already exposed 
that a pituitary adenoma grow out of a single cell. So some-
times it is impossible for radical resection of some NFPAs 
in histological level, and the remnant tumor can potentially 
regrow since residual cells retain their ability to proliferate.
Prognostic significance of HMGA1
The HMGA protein family includes HMGA1 and the 
closely related HMGA2 protein, which are non-histone 
chromosomal proteins that target the minor groove of AT-
rich DNA strands through their adenine/thymine-binding 
motifs [27].HMGA overexpression is a feature of cancers 
of the colon, rectum, breast, pancreas, ovary, lung, esopha-
gus, and testis, among others, and can be used to predict 
patient prognosis and drug response [28]. HMGA overex-
pression reflects the dysregulation of cell cycle-related pro-
teins in pituitary adenomas and is associated with tumor 
invasion through interaction with the RB-E2F1 pathway 
[12]. It has been reported that HMGA proteins upregulate 
cyclin B2 expression, which is correlated with human pitui-
tary tumorigenesis [29]. However, there is no obvious rela-
tionship between the HMGA-1 and tumor regrowth [30]. 
HMGA1 is a therapeutic target in pancreatic cancer [31]. 
Here we found that HMGA1 was upregulated in recurrent 
and regrowthtumors as compared to primary tumors, sug-
gesting that it plays a significant role in NFPA progression.
Prognostic significance of Ki‑67
Ki-67 is an immunohistochemical marker routinely used 
in pituitary adenomas, but its prognostic significance is 
debated [18]. Previous studies have reported Ki-67 positiv-
ity rates of 2.7–15% [32–34]. Several studies have explored 
the possibility of using Ki-67 as a prognostic marker of 
tumor recurrence or regrowth [30]. One study reported that 
tumorigenesis was correlated with a Ki-67 LI >2% [40]; 
others have demonstrated that an LI >2.2% was associated 
with residual tumor growth [30] or that an LI >3% was a 
strong prognostic factor for pituitary adenoma recurrence/
progression [35]. However, some investigators have found 
no correlation between Ki-67 expression and post-operative 
tumor behavior [36]. We found a Ki-67 LI of 0–12.4% asso-
ciated with moderate staining intensity (2+) with no dif-
ference between primary/residual and recurrent/regrowth 
adenomas. The elevated Ki-67 index revealed a strong ten-
dency which suggests that Ki-67 plays some extent role in 
adenoma progression. Some authors had a similar conclu-
sion. Micko revealed a strong tendency between invasive 
and non-invasive adenoma, and no statistically significant 
correlation to higher MIB-1 in invasive cases [37]. Indeed, 
there was no association between Ki-67 LI and Knosp clas-
sification, which were similar in adenomas with total and 
partial surgical removal [38].
Prognostic significance of MDM2
MDM2 is an oncogene that promotes tumor transformation, 
invasion, and metastasis in a p53-independent manner [39]. 
MDM2 negatively regulates p53 via various mechanisms 
such as cell cycle control, genome stability, apoptosis, and 
tumor neoangiogenesis by ubiquitination, transcription 
factor activation, and regulation of mRNA stability [40].
MDM2 is overexpressed in various human tumors, includ-
ing sarcoma, leukemia, breast carcinoma, melanoma, and 
glioblastoma [41]. A recent study detected MDM2 nuclear 
expression in 21.3% of malignant pleural mesothelioma 
patients, which was correlated with worse prognosis [42]. 
The Nutlin analog RO5503781 targets the p53-binding site 
on MDM2 protein and increases its potency [43].In this 
study, MDM2 was detected in 55% of primary and 95% 
of recurrent NFPA specimens, while MDM2 positivity 
was observed in 60% of primaryand in 100% of regrowth 
specimens. The higher expression MDM2 in recurrent 
Table 3  The HMGA1, 
MDM2,Ki67 and RB level in 
regrowth group
Gene HMGA1 MDM2 Ki67 RB
Classification (−) (+) H-score (−) (+) H-Score (−) (+) H-Score (−) (+) H-score
Residual 11 4 16.84 6 9 71.58 14 1 2.52 1 14 91.05
Regrowth 3 12 76.67 0 15 146 14 1 3,43 1 14 126.7
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and regrowthtumors indicate an associated with NFPA 
progression.
Prognostic significance of RB
The RB tumor suppressor directly and indirectly modulates 
tumor development as a negative regulator of the cell cycle 
via interaction with members of the E2F family [44]. In 
fact, RB inhibits both cell cycle progression and apoptosis 
[45]. Although we found no difference in RB expression 
among groups, all specimens showed positive RB expres-
sion, suggesting that RB is involved in the development of 
NFPA.
Conclusions
In this study, we found that NFPA recurrence and regrowth 
behave in a similar fashion. HGMA1 and MDM2 can 
potentially serve as therapeutic targets or biomarkers for 
NFPA, whereas. Ki-67 is an important prognostic marker 
of NFPA progression. Additional studies with a larger 
study population are needed to confirm these findings.
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